Analyst Price Targets — ANRO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 27, 2026 10:49 am | Patrick Trucchio | H.C. Wainwright | $50.00 | $21.06 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Alto Neuroscience (ANRO) |
| May 18, 2026 11:33 am | — | Robert W. Baird | $36.00 | $22.98 | TheFly | Alto Neuroscience price target lowered to $36 from $38 at Baird |
| May 14, 2026 11:55 am | Laura Chico | Wedbush | $24.00 | $22.85 | TheFly | Alto Neuroscience price target raised to $24 from $21 at Wedbush |
| March 16, 2026 2:56 pm | Andrew Tsai | Jefferies | $35.00 | $24.78 | StreetInsider | Alto Neuroscience (ANRO) PT Raised to $35 at Jefferies |
| February 17, 2026 12:13 pm | Thomas Shrader | BTIG | $28.00 | $16.89 | TheFly | Alto Neuroscience price target raised to $28 from $27 at BTIG |
| October 20, 2025 3:05 pm | — | Robert W. Baird | $16.00 | $11.07 | TheFly | Alto Neuroscience price target raised to $16 from $10 at Baird |
| October 23, 2024 6:24 am | Brian Skorney | Robert W. Baird | $10.00 | $14.53 | StreetInsider | Alto Neuroscience (ANRO) PT Lowered to $10 at Baird |
| June 20, 2024 12:50 pm | Brian Skorney | Robert W. Baird | $32.00 | $11.11 | StreetInsider | Baird on Alto Neuroscience (ANRO): 'Incrementally positive on Phase 2 CIAS initiation' |
Latest News for ANRO
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options, announced today the pricing of an underwritten registered direct offering of 3,776,436 shares of its common stock at a price of $26.48 per share.…
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today highlighted the publication in Nature Medicine of PRIME-PRAXOL, an independent, randomized, double-blind, placebo-controlled trial of the dopamine agonist pramipexole in patients with mood disorders and clinically significant anhedonia. The study was conducted and independently funded by investigators at Lund…
Alto Neuroscience, Inc. (âAltoâ) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuro
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Andrew Miller, Ph.D. to its Board of Directors, effective May 27, 2026. “We are thrilled to welcome Andrew to Alto's Board at a transformative time for…
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today congratulates founder and CEO Amit Etkin, M.D., Ph.D. on receiving the Transformational Research Award from the VP&S Alumni Association at Columbia University Vagelos College of Physicians…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ANRO.
U.S. House Trading
No House trades found for ANRO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.